Page 8 - கிழக்கு கூட்டுறவு புற்றுநோயியல் குழு News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Cemiplimab monotherapy for first-line treatment of advanced non-small- by Ahmet Sezer, Saadettin Kilickap et al

Abstract Background: We aimed to examine cemiplimab, a programmed cell death 1 inhibitor, in the first-line treatment of advanced non-small-cell lung cancer with programmed cell death ligand 1 (PD-L1) of at least 50%. Methods: In EMPOWER-Lung 1, a multicentre, open-label, global, phase 3 study, eligible patients recruited in 138 clinics from 24 countries (aged ≥18 years with histologically or cytologically confirmed advanced non-small-cell lung cancer, an Eastern Cooperative Oncology Group performance status of 0–1; never-smokers were ineligible) were randomly assigned (1:1) to cemiplimab 350 mg every 3 weeks or platinum-doublet chemotherapy. Crossover from chemotherapy to cemiplimab was allowed following disease progression. Primary endpoints were overall survival and progression-free survival per masked independent review committee. Primary endpoints were assessed in the intention-to-treat population and in a prespecified PD-L1 of at least 50% population (per US Food and Drug

Regeneron pharmaceuticalsDrug administrationEastern cooperative oncology groupBetween juneகிழக்கு கூட்டுறவு புற்றுநோயியல் குழுஇடையில் ஜூன்

Targeted Drug Yields Durable Responses in Rare Blood Neoplasm

email article Three-quarters of patients with the rare blood disorder advanced systemic mastocytosis responded to treatment with avapritinib (Ayvakit), an interim analysis of a phase II trial found. Among 32 patients treated with daily avapritinib in the PATHFINDER study, 19% had a complete remission (CR) with partial hematologic recovery, 31% had a partial response, and 25% achieved stable disease, with responses observed in all disease subtypes, reported Daniel DeAngelo, MD, PhD, of the Dana-Farber Cancer Institute in Boston. Avapritinib at a starting dose of 200 mg induced rapid, durable, and improving responses, DeAngelo said during his presentation at the American Association for Cancer Research virtual meeting. Reductions were seen in disease burden based on bone marrow mast cells, reduction in serum tryptase,

United statesDana farber cancer instituteDaniel deangeloIan ingramAmerican association for cancer researchInternational working groupEuropean competence network on mastocytosisMyeloproliferative neoplasms researchEastern cooperative oncology groupAmerican associationCancer researchEuropean competence networkMedpage todayDeputy managing editorஒன்றுபட்டது மாநிலங்களில்டானா ஃபார்‌பர் புற்றுநோய் நிறுவனம்

Efficacy and safety of pembrolizumab in patients with advanced mesothelioma in the open-label, single-arm, phase 2 KEYNOTE-158 study

Efficacy and safety of pembrolizumab in patients with advanced mesothelioma in the open-label, single-arm, phase 2 KEYNOTE-158 study
thelancet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from thelancet.com Daily Mail and Mail on Sunday newspapers.

United statesMerck co incMerck sharp dohme corpEastern cooperative oncology groupNorth americaResponse evaluation criteriaSolid tumorsDohme corpஒன்றுபட்டது மாநிலங்களில்மெர்க் இணை இன்க்கிழக்கு கூட்டுறவு புற்றுநோயியல் குழுவடக்கு அமெரிக்காபதில் மதிப்பீடு அளவுகோல்கள்

[Full text] Primary Tumor Radiotherapy During EGFR-TKI Disease Control

[Full text] Primary Tumor Radiotherapy During EGFR-TKI Disease Control
dovepress.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from dovepress.com Daily Mail and Mail on Sunday newspapers.

National taiwan university hospitalT ai peiEteläuomen läiUnited statesNational centerPharmacogenomics labResearch of national taiwan university hospitalEastern cooperative oncology groupEnd resultsInstitutional review boardTaichung veterans general hospitalAmerican joint committeeTaichung veterans generalResponse evaluation criteriaSolid tumorsClinical trial

Health Canada approves new indication for lung cancer treatment option ALUNBRIG®

Share this article First-line indication offers Canadians with advanced lung cancer new treatment options TORONTO, March 17, 2021 /CNW/ - Takeda Canada Inc. is pleased to announce that Health Canada has issued ALUNBRIG ® (brigatinib tablets) marketing authorization without conditions as monotherapy for the first-line treatment of adult patients with anaplastic lymphoma kinase positive (ALK+) locally advanced (not amenable to curative therapy) or metastatic non-small cell lung cancer (NSCLC). 1 The approval is based on results from the phase 3 ALTA-1L trial which evaluated 275 patients and showed that once-daily ALUNBRIG ® was superior to crizotinib on measures of efficacy and tolerability making it a promising first-line treatment option.

South koreaPopats brigatinibGeoffrey liuAmanda jacobsDavid fysheTakeda canada incBetter healthUniversity health networkPrincess margaret cancer care centreTakeda pharmaceutical company limitedTakeda pharmaceutical companyEastern cooperative oncology groupCanadian cancer societyHealth canadaPharmaceuticals incTakeda canada